Review of the rebound phenomenon in new anticoagulant treatments

References

• Marshall J. Rebound phenomena after anticoagulant therapy in cerebrovascular disease. Circulation 1963;28:329–32
   PubMed Web of Science ®Google Scholar
• Sharland DE. Effect of cessation of anticoagulant therapy on the course of ischaemic heart disease. Br Med J 1966;2:392–3
   PubMed Web of Science ®Google Scholar
• Granger CB, Miller JM, Bovill EG, et al. Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes. Circulation 1995;91:1929–35
   PubMed Web of Science ®Google Scholar
• Gold HK, Torres FW, Garabedian HD, et al. Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris. J Am Coll Cardiol 1993;21:1039–47
   PubMed Web of Science ®Google Scholar
• Theroux P, Waters D, Lam J, et al. Reactivation of unstable angina after the discontinuation of heparin. New Engl J Med 1992;327:141–5
   PubMed Web of Science ®Google Scholar
• Genewein U, Haeberli A, Straub PW, Beer JH. Rebound after cessation of oral anticoagulant therapy: the biochemical evidence. Br J Haematol 1996;92:479–85
   PubMed Web of Science ®Google Scholar
• Palareti G, Legnani C, Guazzaloca G, et al. Activation of blood coagulation after abrupt or stepwise withdrawal of oral anticoagulants – a prospective study. Thromb Haemost 1994; 72:222–6
   PubMed Web of Science ®Google Scholar
• Grip L, Blomback M, Schulman S. Hypercoagulable state and thromboembolism following warfarin withdrawal in post-myocardial-infarction patients. Eur Heart J 1991;1225–33
   Google Scholar
• Van Cleve R. The rebound phenomenon – fact or fancy? Experience with discontinuation of long-term anticoagulation therapy after myocardial infarction. Circulation 1965;32: 878–80
   PubMed Web of Science ®Google Scholar
• Ascani A, Lorio A, Agnelli G. Withdrawal of warfarin after deep vein thrombosis: effects of a low fixed dose on rebound thrombin generation. Blood Coagul Fibrinolysis 1999;10:291–5
   Google Scholar
• Michaels L. Recurrence of thromboembolic disease after discontinuing anticoagulant therapy. A study of factors affecting incidence. Br Heart J 1970;32:359–64
   PubMedGoogle Scholar
• Nichol ES, Keyes JN, Borg JF, et al. Long-term anticoagulant therapy in coronary atherosclerosis. Am Heart J 1958;55: 142–52
   PubMed Web of Science ®Google Scholar
• Van Cleve RB. Letting go of the bear’s tail. Experience with discontinuation of long-term anticoagulant therapy. J Am Med Assoc 1966;196:1156–8
   Google Scholar
• Bahit MC, Topol EJ, Califf RM, et al. Reactivation of ischemic events in acute coronary syndromes: results from GUSTO-IIb. Global Use of Strategies To Open occluded arteries in acute coronary syndromes. J Am Coll Cardiol 2001;37:1001–7
   Google Scholar
• Flather MD, Weitz JI, Yusuf S, et al. Reactivation of coagulation after stopping infusions of recombinant hirudin and unfractionated heparin in unstable angina and myocardial infarction without ST elevation: results of a randomized trial [OASIS Pilot Study Investigators. Organization to Assess Strategies for Ischemic Syndromes]. Eur Heart J 2000;21: 1473–81
   Google Scholar
• Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease [Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group]. New Engl J Med 1997;337:447–52
   PubMed Web of Science ®Google Scholar
• Bijsterveld NR, Moons AH, Meijers JC, et al. Rebound thrombin generation after heparin therapy in unstable angina. A randomized comparison between unfractionated and low-molecular-weight heparin. J Am Coll Cardiol 2002;39:811–7
   Google Scholar
• Low-molecular-weight heparin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease (FRISC) study group. Lancet 1996;347:561–8
   PubMed Web of Science ®Google Scholar
• Sakharov DV, Rijken DC. The effect of flow on lysis of plasma clots in a plasma environment. Thromb Haemost 2000;83: 469–74
   PubMed Web of Science ®Google Scholar
• Lam SC, Dieter JP, Strebel LC, et al. Rapid dissociation of platelet-rich fibrin clots in vitro by a combination of plasminogen activators and antiplatelet agents. J Pharmacol Exp Ther 1991;259:1371–8
   PubMed Web of Science ®Google Scholar
• Sobel M, Sternbergh WC 3rd, Marques D, Grimsdale AS. A comparative study of heparin responses in arterial and venous thromboembolism using molecular markers for thrombosis. Circulation 1993;88:II426–31
   Google Scholar
• Planes A, Vochelle N, Darmon JY, et al. Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: double-blind randomised comparison of enoxaparin versus placebo. Lancet 1996;348:224–8
   PubMed Web of Science ®Google Scholar
• Dahl OE, Andreassen G, Aspelin T, et al. Prolonged thromboprophylaxis following hip replacement surgery – results of a double-blind, prospective, randomised, placebo-controlled study with dalteparin (Fragmin). Thromb Haemost 1997; 77:26–31
   PubMed Web of Science ®Google Scholar
• Hirsh J. Evidence for the needs of out-of-hospital thrombosis prophylaxis: introduction. Chest 1998;114:113S–114S
   Google Scholar
• Hull RD, Pineo GF, Francis C, et al. Low-molecular-weight heparin prophylaxis using dalteparin extended out-of-hospital vs in-hospital warfarin/out-of-hospital placebo in hip arthroplasty patients: a double-blind, randomized comparison [North American Fragmin Trial Investigators]. Arch Intern Med 2000;160:2208–15
   PubMed Web of Science ®Google Scholar
• Eisenberg PR, Siegel JE, Abendschein DR, Miletich JP. Importance of factor Xa in determining the procoagulant activity of whole-blood clots. J Clin Invest 1993;91:1877–83
   PubMed Web of Science ®Google Scholar
• Dahl OE, Aspelin T, Arnesen H, et al. Increased activation of coagulation and formation of late deep venous thrombosis following discontinuation of thromboprophylaxis after hip replacement surgery. Thromb Res 1995;80:299–306
   PubMed Web of Science ®Google Scholar
• Arnesen H, Dahl OE, Aspelin T, et al. Sustained prothrombotic profile after hip replacement surgery: the influence of prolonged prophylaxis with dalteparin. J Thromb Haemost 2003;1:971–5
   PubMed Web of Science ®Google Scholar
• White RH, Romano PS, Zhou H, et al. Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty. Arch Intern Med 1998;158:1525–31
   PubMed Web of Science ®Google Scholar
• Bergqvist D, Benoni G, Bjorgell O, et al. Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. New Engl J Med 1996;335:696–700
   PubMed Web of Science ®Google Scholar
• Comp PC, Spiro TE, Friedman RJ, et al.; for the Enoxaparin Clinical Trial Group. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. J Bone Joint Surg Am 2001;83–A:336–45
   Google Scholar
• Lassen MR, Borris LC, Anderson BS, et al. Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty – the Danish Prolonged Prophylaxis (DaPP) Study. Thromb Res 1998;89:281–7
   PubMed Web of Science ®Google Scholar
• Eikelboom JW, Quinlan DJ, Douketis JD. Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials. Lancet 2001;358:9–15
   Google Scholar
• Hull RD, Pineo GF, Stein PD, et al. Extended out-of-hospital low-molecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: a systematic review. Ann Intern Med 2001;135:858–69
   PubMed Web of Science ®Google Scholar
• Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126:338S–400S
   Google Scholar
• Turpie AG, Gallus AS, Hoek JA. A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. New Engl J Med 2001;344:619–25
   Google Scholar
• Eriksson BI. Improvements in the prevention of postoperative venous thromboembolism in hip fracture patients. Orthopedics 2003;26:s851–s858
   PubMed Web of Science ®Google Scholar
• Eriksson B, Bauer KA. The PENTHIFRA study: comparison of the first synthetic factor Xa inhibitor with low molecular weight heparin in the prevention of venous thromboembolism after hip fracture surgery. Blood 2000;96:490
   Google Scholar
• Eriksson BI, Bauer KA, Lassen MR, Turpie AG. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. New Engl J Med 2001;345:1298–304
   PubMed Web of Science ®Google Scholar
• Lassen MR, Bauer KA, Eriksson BI, Turpie AG. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. Lancet 2002;359: 1715–20
   PubMed Web of Science ®Google Scholar
• Bauer K. The Pentamaks study: comparison of the first synthetic factor Xa inhibitor with low molecular weight heparin the prevention of venous thromboembolism after elective major knee surgery. Blood 2000;96:490–1
   Google Scholar
• Bauer KA, Eriksson BI, Lassen MR, Turpie AG. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. New Engl J Med 2001;345:1305–10
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Lassen MR. Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled, double-blind study. Arch Intern Med 2003;163:1337–42
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Bergqvist D, Kalebo P, et al. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial. Lancet 2002;360:1441–7
   PubMed Web of Science ®Google Scholar
• Eriksson H, Eriksson UG, Frison L, et al. Pharmacokinetics and pharmacodynamics of melagatran, a novel synthetic LMW thrombin inhibitor, in patients with acute DVT. Thromb Haemost 1999;81:358–63
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Arfwidsson AC, Frison L, et al. A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in Orthopaedic surgery. Thromb Haemost 2002;87:231–7
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Agnelli G, Cohen AT, et al. The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study. J Thromb Haemost 2003;1:2490–6
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Agnelli G, Cohen AT, et al. Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement. Thromb Haemost 2003;89:288–96
   PubMed Web of Science ®Google Scholar
• Colwell Jr CW, Berkowitz SD, Davidson BL, et al. Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, double-blind study. J Thromb Haemost 2003;1:2119–30
   PubMed Web of Science ®Google Scholar
• Schulman S, Wahlander K, Lundstrom T, et al. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. New Engl J Med 2003;349:1713–21
   PubMed Web of Science ®Google Scholar
• Francis CW, Berkowitz SD, Comp PC, et al. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. New Engl J Med 2003;349:1703–12
   PubMed Web of Science ®Google Scholar
• Petersen P, Grind M, Adler J. Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. SPORTIF II: a dose-guiding, tolerability, and safety study. J Am Coll Cardiol 2003;41:1445–51
   Google Scholar
• Olsson SB. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 2003;362:1691–8
   PubMed Web of Science ®Google Scholar
• Albers GW. Stroke prevention in atrial fibrillation: pooled analysis of SPORTIF III and V trials. Am J Manag Care 2004;10: S462-S469 [discussion S9-S73]
   Google Scholar
• Montalescot G, Bal-dit-Solier C, Chibedit D, et al. Comparison of effects on markers of blood cell activation of enoxaparin, dalteparin, and unfractionated heparin in patients with unstable angina pectoris or non-ST-segment elevation acute myocardial infarction (the ARMADA study). Am J Cardiol 2003; 91:925–30
   PubMed Web of Science ®Google Scholar
• Mehta SR, Steg PG, Granger CB, et al. Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: Arixtra Study in Percutaneous Coronary Intervention: a Randomized Evaluation (ASPIRE) Pilot Trial. Circulation 2005;111:1390–7
   PubMed Web of Science ®Google Scholar
• Turpie AG, Bauer KA, Eriksson BI, Lassen MR. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet 2002;359:1721–6
   PubMed Web of Science ®Google Scholar
• Turpie AG, Eriksson BI, Lassen MR, Bauer KA. A meta-analysis of fondaparinux versus enoxaparin in the prevention of venous thromboembolism after major orthopaedic surgery. J South Orthop Assoc 2002;11:182–8
   PubMedGoogle Scholar
• European Medicines Agency. EMEA; 2004
   Google Scholar
• Wallentin L, Wilcox RG, Weaver WD, et al. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. Lancet 2003;362:789–97
   PubMed Web of Science ®Google Scholar
• Christersson C, Oldgren J, Bylock A, Siegbahn A, Wallentin L. Reactivation of coagulation activity after cessation of the oral direct thrombin inhibitor ximelagatran is independent of time after acute myocardial infarction. Eur Heart J 2005;26 [Abstract Supplement]:482
   Google Scholar
• FDA. AstraZeneca Exanta liver toxicity outweighs benefit. Washington (DC): Food and Drug Administration; 2004
   Google Scholar
• FDA. Integrated executive summary of FDA review for NDA 21–686 Exanta (Ximelagatran). Washington (DC): Food and Drug Administration; 2004
   Google Scholar
• Gurewich V. Ximelagatran – promises and concerns. J Am Med Assoc 2005;293:736–9
   Web of Science ®Google Scholar
• Fiessinger JN, Huisman MV, Davidson BL, et al. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. J Am Med Assoc 2005;293:681–9
   PubMed Web of Science ®Google Scholar
• Palareti G, Legnani C. Warfarin withdrawal. Pharmacokinetic– pharmacodynamic considerations. Clin Pharmacokinet 1996;30:300–13
   Google Scholar
• Lauer MA, Houghtaling PL, Peterson JG, et al. Attenuation of rebound ischemia after discontinuation of heparin therapy by glycoprotein IIb/IIIa inhibition with eptifibatide in patients with acute coronary syndromes: observations from the platelet IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial. Circulation 2001;104:2772–7
   PubMed Web of Science ®Google Scholar
• Hansen JB, Naalsund T, Sandset PM, Svensson B. Rebound activation of coagulation after treatment with unfractionated heparin and not with low molecular weight heparin is associated with partial depletion of tissue factor pathway inhibitor and antithrombin. Thromb Res 2000;100:413–7
   PubMed Web of Science ®Google Scholar
• Gerotziafas GT, Depasse F, Chakroun T, Van Dreden P, Samama MM, Elalamy I. Comparison of the effect of fondaparinux and enoxaparin on thrombin generation during in-vitro clotting of whole blood and platelet-rich plasma. Blood Coagul Fibrinolysis 2004;15:149–56
   Google Scholar
• Komatsu Y, Hayashi H. Most clot-bound thrombin activity is inhibited by plasma antithrombin during clot aging, but a very small fraction survives. Biol Pharm Bull 2000;23:502–5
   PubMed Web of Science ®Google Scholar
• Linder R, Blomback M, Egberg N, Grip L. Thrombin inhibitors suppress the thrombin–thrombomodulin-mediated generation of activated protein C. Thromb Res 1999;95:117–25
   PubMed Web of Science ®Google Scholar
• Furugohri T, Shiozaki Y, Muramatsu S, et al. Different anti-thrombotic properties of factor Xa inhibitor and thrombin inhibitor in rat thrombosis models. Eur J Pharmacol 2005;514:35–42
   PubMed Web of Science ®Google Scholar